Forgot your password?
Atopic dermatitis is a chronic, inflammatory skin disease characterised by intense itch and eczematous lesions
The study demonstrated a 63.3% combined pathologic response rate, with 50.6% of patients achieving the primary endpoint of complete pathologic response
There was a low incidence of adverse events and, even when applied to areas of sensitive skin, Vtama was well tolerated
The decision is based on three pivotal phase 3 studies: ADvocate 1, ADvocate 2 and ADhere
The research was published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society
The collaboration hopes to generate novel insights on patient outcomes in a real-world setting
The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival
The positive data has been published in The New England Journal of Medicine
The phase 2/3 study is expected to be conducted at approximately 238 sites worldwide